Astellas Pharma said the FDA has accepted its supplemental new drug application for Tarceva, or erlotinib, as a first-line treatment for EGFR-positive metastatic or locally advanced nonsmall-cell lung cancer. The application was given priority-review designation.
FDA will consider expanded use of Astellas' cancer drug erlotinib
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|